Finally, in the KEYNOTE-048 clinical trial, Pembrolizumab (immunotherapy that targets PD-L1) with chemotherapy improved overall survival versus Cetuximab (EGFR targeted therapy) with chemotherapy in patients with head and neck squamous cell carcinoma [67]. Here, CD274 is linked to head and neck squamous cell carcinoma.